Epoetin alfa

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameEpoetin alfa
Drug Alias Name依泊汀αr-HuEPO (Amgen/Janssen)Epoetin-α (Amgen/Janssen)促红素α阿法依伯汀 +[22] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsCardiac Surgical ProceduresSolid tumoursHealthy Aging +[66] 
Global Approved IndicationsAnemia
Approved Indications in ChinaAnemia
Original Approved Country/TerritoryUnited States
Original Approved Date1989/06/01
Country/TerritoryBelgiumBulgariaCanada +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen IncJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesMedical Research Institute Of New ZealandBio Sidus SaUniversity Of California San Francisco +[11] 
Inactive CompaniesJanssen-Ortho Inc., CanadaAzidus BrasilJanssen-Cilag International Nv +[30] 
Active IndicationsWounds, StabMultiple TraumaAsphyxia Neonatorum +[9] 
Inactive IndicationsCardiac Surgical ProceduresSolid tumoursHealthy Aging +[57] 

Other Information

ATC CodeB03XA01
Related LinksWikipediaDrugBankKEGG